一种具有类作用的微RNA,miR-31,可以抑制乳腺癌转移
Scott Valastyan1, Ferenc Reinhardt, Nathan Benaich
1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Cell
|June 16, 2009
概括
像miR-31这样的微RNA可以通过向多个基因来抑制乳腺癌转移. 抑制乳腺癌细胞中的miR-31促进转移,突出显示了它在防止瘤扩散方面的关键作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 微RNAs (miRNAs) 是基因表达的关键调节者.
- 它们能够准多个基因的能力使得它们非常适合复杂的过程,如瘤转移.
- 微RNAs的失调与包括乳腺癌在内的各种癌症有关.
研究的目的:
- 研究miR-31在乳腺癌转移中的作用.
- 为了确定miR-31是否可以通过对目标基因的协调调节来抑制转移.
- 探索针对乳腺癌中的miR-31的治疗潜力.
主要方法:
- 在人类乳腺癌患者中,miR-31表达与转移的相关性分析.
- 在侵袭性乳腺瘤细胞中过度表达miR-31,以评估转移抑制.
- 在非侵袭性乳腺癌细胞中使用稳定的microRNA海绵策略进行miR-31的体内抑制.
- 分析原发性瘤发育和转移相关的表型.
- 研究RhoA再表达对miR-31介导的转移抑制的影响.
主要成果:
- 在人类乳腺癌中,miR-31表达与转移相反相关.
- 过度表达miR-31可以抑制侵袭性乳腺瘤细胞的转移.
- 在非侵袭性细胞中抑制miR-31可促进转移,而不会影响原发性瘤生长.
- miR-31抑制了入侵-转移级联的多个步骤,包括本地入侵,扩散和殖民.
- miR-31通过抑制转移促进基因 (如RhoA.
- 罗亚的重新表达部分扭转了miR-31诱导的转移抑制.
结论:
- miR-31作为乳腺癌转移的强有力的抑制剂.
- miR-31采用多种机制,通过向关键转移促进基因来抑制瘤的扩散.
- miR-31代表了预防乳腺癌转移的潜在治疗标.
相关概念视频
MicroRNAs
21.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K


